Deta推出的AI浏览器,帮你浏览、组织和理解整个互联网
关于 Mool
Mool | Investment Research & Portfolio Intelligence Skip to content For individuals For firms Research Markets Platform Pricing Talk to sales Sign in Start free Open menu For individuals → For firms → Research → Markets → Platform → Pricing → Start free Sign in Talk to sales Investment research. Portfolio intelligence. Continuous financial intelligence, built around you. Understand the businesses you invest in. Bring your holdings together. Get weekday briefs on the companies you own and follow. Find a company in our published coverage Search Read published analysis without an account. Enter at least 3 characters. Browse all research Connect your portfolio 10 days of Pro, or of Firm on a work email address to start. No card needed. For your firm’s clients, funds and portfolios Your intelligence, connected Company research → your portfolio Understand. Connect. Stay informed. 01 Discover a company 02 Bring your holdings 03 Follow what changes Explore the published coverage OneSource Specialty Pharma Inc. NSE : ONESOURCE · Report 27 Oct 2026 LTIMindtree Ltd NSE : LTM · Report 27 Oct 2026 RailTel Corporation of India Ltd. NSE : RAILTEL · Report 27 Oct 2026 Start with the evidence. Make it relevant to you. Follow companies or bring in your portfolio. Weekday briefs connect updates to your holdings and the companies you follow. Explore the company intelligence Inspect the method Research with its sources and working shown Weekday briefs on holdings and followed companies Your questions, files and firm's method Start with something useful Read the evidence behind a business. Published business-model and financial analysis is free to read. The full report and Mool’s research view open with Individual or above . 485 companies across 11 sectors in published coverage. An excerpt from Mool’s published research OneSource Specialty Pharma Inc. NSE : ONESOURCE · Report 27 Oct 2026 Business model and financial foundation OneSource (NSE: ONESOURCE), Pharmaceutical CDMO (biologics, drug-device combinations, sterile injectables, softgels): revenue of ₹1,422 crore in FY26 (-1.6% on FY25), an EBITDA margin of 21.4%, net profit of ₹-73.8 crore and net debt of ₹1,176 crore. Read the analysis and its sources Figures from this public analysis Revenue, FY26 (₹ crore) 1,422 consolidated Revenue growth, FY26 -1.6% on FY25 EBITDA margin, FY26 21.4% EBITDA (Company EBITDA, excluding other income and exceptional items) / revenue The figures retain the periods and comparisons stated
访问提示
本站仅提供官网信息与访问导航,不代表对该网站的产品、服务或交易作出担保。访问外部网站时,请核对网址,注意账号和财产安全。
同类型网站
查看分类Lumina作为一款AI驱动的学术搜索引擎,以其精准、高效的搜索功能和广泛的学术资源,成为了学术研究领域的重要工具。通过使用Lumina,研究人员可以更加高效地进行文献检索和资源管...
SeekAll是一个创新的浏览器插件,通过整合多个AI搜索站点,为用户提供了一个高效、准确且用户友好的搜索体验。
AI驱动的学术论文搜索引擎